Lit­tle Nor­we­gian biotech will sell it­self for parts, as it plans to ex­plore 's­trate­gic op­tion­s'

A few weeks af­ter an­nounc­ing a re­or­ga­ni­za­tion and shut­ting down its on­ly clin­i­cal tri­al, Nordic Nanovec­tor has de­cid­ed to es­sen­tial­ly call it quits.

The Nor­we­gian com­pa­ny re­vealed late Thurs­day af­ter­noon that it will “ex­plore strate­gic op­tions,” biotech code­s­peak for sell­ing it­self and/or its as­sets. The move will wrap up what’s been a 13-year jour­ney since Nordic Nanovec­tor’s 2009 found­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER